3-(4-(5-Aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride

Catalog No. :
ACFLAB625
CAS No. :
2595367-27-2
Molecular Formula :
C18H24ClN3O3
Molecular Weight :
365.86

IUPAC Name:3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride

3-(4-(5-Aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$142.00Login to see priceIn stockInquiry
100mg95%$241.00Login to see priceIn stockInquiry
250mg95%$414.00Login to see priceIn stockInquiry
1g95%$1179.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(4-(5-Aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
IUPAC Name3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
MDL No.MFCD32708541
Molecular FormulaC18H24ClN3O3
Molecular Weight365.86
SMILESO=C(C(N(CC1=C2C=CC=C1CCCCCN)C2=O)CC3)NC3=O.[H]Cl
InChI KeyMDQAJUCZXLGNMH-UHFFFAOYSA-N
Synonym3-(4-(5-Aminopentyl)-1-oxoisoindolin-2-yl) piperidine-2,6-dione hydrochloride;2,6-Piperidinedione, 3-[4-(5-aminopentyl)-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-, hydrochloride (1:1)
CAS No.2595367-27-2

Safety Data

Pictogram
Health hazard
Signal Word
Achtung
Hazard Statement(s)
H361-H373
Precautionary Statement(s)
P201-P202-P260-P280-P308+P313-P405-P501

Synthetic Route by SureRoute

1. ACFLAB625 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLBPH504 route compound structure diagram
    ACLBPH5042136248-15-0 In Stock
  2. Then
  3. ACFLAB625 route product structure diagram
    ACFLAB6252595367-27-2 In Stock
Inquiry

2. ACFLAB625 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFLAB625 route product structure diagram
    ACFLAB6252595367-27-2 In Stock
Inquiry

Comments (0)